We analysed CD4 + T cells in three seropositive (defined as positive for rheumatoid factor or anti-citrullinated-peptide antibody) rheumatoid arthritis (RA) synovial tissue samples with dense leukocyte infiltrates, using a mass cytometry panel designed to interrogate both stromal and leukocyte populations (Extended Data Table 1 ). Twodimensional visualization of the multidimensional cytometry data using viSNE (visualization using t-Distributed Stochastic Neighbor Embedding) 5 revealed a heterogeneous CD4 + T-cell population with distinct expression patterns of five activation markers (PD-1, MHC II, ICOS, CD69, and CD38) (Fig. 1a) . Notably, a large population of cells with high PD-1 expression clustered together in each of the three samples (Fig. 1a, Extended Data Fig. 1a) . Biaxial gating of data from six seropositive RA synovial tissue samples confirmed high expression of PD-1 on ~ 25% of synovial CD4 + T cells, the majority of which co-expressed MHC II and/or ICOS (Fig. 1b, Extended Data Fig. 1b, Extended Data Table 2 ).
In a complementary approach, 11-dimensional flow cytometric analysis of memory CD4 + T cells from paired synovial fluid and blood samples from three seropositive RA patients also revealed a large population of synovial PD-1 hi CD4
+ T cells, a subset of which co-expressed MHC II and/or ICOS (Extended Data Fig. 1c ). Approximately 30% of synovial fluid CD4 + T cells displayed high PD-1 expression, mirroring results from synovial tissue (Fig. 1c, Extended Data Fig. 1c, d) . The frequency of PD-1 hi CD4
+ T-cell populations was over fivefold higher in seropositive RA synovial fluid (n = 9) compared to synovial fluid from 19 patients with seronegative inflammatory arthritides (seronegative RA n = 2, spondyloarthropathy n = 8, juvenile idiopathic arthritis n = 9) (Fig. 1c) .
The marked expansion of PD-1 hi cells specifically in seropositive RA, a disease characterized by autoantibody production and frequent synovial T-B-cell aggregates 6, 7 , led us to consider whether synovial PD-1 
CD4
+ T cells with a similar multidimensional phenotype, including increased expression of MHC II and ICOS, also appeared in the circulation, albeit at much lower frequencies (Extended Data Figs 1c, e, 2a, b 
ICOS
+ cells were also increased in blood of seropositive RA patients (Extended Data Fig. 2c ). By contrast, the frequencies of letter reSeArCH
+ cells and cells with intermediate PD-1 expression were not increased (Extended Data Fig. 2d, e) .
PD-1 hi CXCR5 − cell frequencies were more robustly increased in seropositive RA patients with moderate or high disease activity (clinical disease activity index (CDAI) > 10) (Fig. 1f ) . The frequency of PD-1 hi CXCR5
− cells did not vary with other clinical parameters such as age, sex, disease duration, use of methotrexate or biologic therapies, or serum anti-CCP antibody titer (Extended Data Fig. 2f-h) . In an independent cohort of 23 seropositive RA patients assayed before and after starting a new RA medication, there was a significant correlation between reduction in disease activity and reduction in the frequency of PD-1 hi CXCR5 − T cells (Extended Data Fig. 2i ). 
CXCR5
− cells decreased significantly in the 18 patients whose disease activity decreased after treatment escalation (Fig. 1g , Extended Data Fig. 2j ).
As high PD-1 expression is often considered indicative of an exhausted state 8, 9 , we assessed the function of synovial PD-1 hi CXCR5 − cells. Surprisingly, despite a lack of CXCR5 expression, PD-1 hi CD4 + T cells sorted from seropositive RA synovial fluid showed a > 100-fold increase in IL21 mRNA expression and a > 1,000-fold increase in CXCL13 mRNA expression, as well as higher levels of IFNG and IL10, compared to PD-1 − T cells, with the highest expression in PD-1 hi MHC-II + cells (Fig. 2a , sorted as in Extended Data Fig. 1e ). By contrast, IL2 showed a trend towards lower expression in PD-1 hi cells.
Consistent with mRNA expression, PD-1 hi CXCR5 − cells sorted from RA synovial fluid more frequently produced IL-21 (~ 30%), but less frequently produced IL-2, compared to PD-1 − or PD-1 int cells, after stimulation with PMA and ionomycin (Fig. 2b) . Stimulation with anti-CD3/CD28 antibody beads induced greater CXCL13 production than did PMA and ionomycin. Notably, after anti-CD3/CD28 antibody stimulation, ~ 25% of PD-1 hi CXCR5
− cells produced CXCL13, but not IL-2, compared to < 1% of PD-1 − or PD-1 int cells (Fig. 2b) . High IL-21 and CXCL13 production by synovial fluid PD-1 hi CXCR5 − CD4 + T cells indicates that these cells are not globally exhausted, and instead suggests a possible B-cell helper function.
PD-1 hi MHC-II + cells in seropositive RA synovial fluid also expressed high mRNA levels of the transcription factors MAF and BATF and the signalling adaptor SAP (encoded by SH2D1A), three factors important for T FH cell development or function 3 (Extended Data Fig. 3a) . However, BCL6, a transcription factor characteristically expressed in T FH cells, was not elevated in synovial fluid PD-1 hi cells, whereas BLIMP1, a transcription factor typically downregulated in T FH cells, was upregulated 3,10 (Extended Data Fig. 3a ). Intracellular flow cytometry confirmed that BLIMP1 was significantly elevated in PD-1 hi CXCR5
− cells, but not PD-1 hi CXCR5 + cells, from seropositive RA synovial samples (Fig. 2c, d + cells. b, PD-1 hi T-cell frequency in RA synovial tissue (n = 6). c, PD-1 hi CD4 + T-cell frequencies in synovial fluid from seropositive RA (n = 9) and seronegative inflammatory arthritides (n = 19). d, PD-1 hi cell frequencies in seropositive RA synovial fluid (n = 9) and tissue (n = 10). e, Percentage of PD-1 hi CXCR5 − cells within memory CD4 + T cells in seropositive RA (n = 42), seronegative RA (n = 16), spondyloarthropathy (SpA, n = 11), and control (n = 35) patient blood. f, PD-1 hi frequency in blood of seropositive RA patients with low (n = 14) or moderate-high (n = 28) disease activity. g, PD-1 hi CXCR5 − CD4 + T cell and plasmablast frequencies in blood before and after RA treatment escalation (n = 18). Mean ± s.d. (b-d), median ± interquartile range (e, f). * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 by Mann-Whitney (c, d), Kruskal + cells showed significantly increased expression of 11 proteins, including TIGIT, ICOS, CD38, and CD57, and significantly decreased expression of 5 proteins, including CD25 and CD127, compared to PD-1 − CXCR5 − cells (Fig. 3b) . Unlike TIGIT, the inhibitory receptors TIM-3, LAG-3, and CTLA-4 did not appear to be enriched on PD-1 hi CXCR5
− cells (Extended Data Fig. 4c ). Compared to PD-1 hi CXCR5 + cells, PD-1 hi CXCR5 − cells showed lower expression of CCR7 and CD27 but higher CD44 and T-bet (Fig. 3b, + cells beyond CXCR5 expression alone. Sixty-six genes were differentially expressed when comparing all of the PD-1 hi populations to the PD-1 − populations (log fold change > 1.2, FDR < 0.01, Extended Data Table 3 ), including a set of genes previously reported to be elevated in T FH cells, such as MAF, TIGIT, and SLAMF6 (refs 14, 15 
CCR2
− cell populations sorted from blood were stimulated in vitro and re-evaluated at different time points (Extended Data Fig. 5a , b). After 7 days, the majority of PD-1 hi cells that began as CXCR5 −
+ cells remained CCR2 + , whereas less than 5% of these cells acquired CXCR5 (Extended Data Fig. 5c, d) + cells (Fig. 4a, b) . PD-1 hi CXCR5 − cells from synovial fluid and blood also enhanced IgG production in the co-cultures (Fig. 4c) . Neutralization of IL-21 inhibited plasma cell differentiation induced by both blood PD-1 hi CXCR5
− cells and PD-1 hi CXCR5 + cells by ~ 90% (Fig. 4d) . Expression of SLAMF5, a factor that is important for interactions between B cells and T cells 4 , was elevated on both PD-1 hi CXCR5
− and PD-1 hi CXCR5 + cells, and antibody blockade of SLAMF5, but not SLAMF6, completely abrogated plasma cell differentiation and IgG production (Fig. 4e, Extended Data Fig. 6a-c) . Consistent with a link in vivo, RA treatment escalation reduced the frequency of circulating plasmablasts in parallel with the reduction in PD-1 hi CXCR5
− T cells (Fig. 1g) . Finally, immunofluorescence microscopy identified CD3 + T cells with bright PD-1 expression in all four seropositive RA synovial samples analysed (Fig. 4f) . CXCR5 was observed on CD20 + B cells and on a minority of PD-1 hi T cells that were enriched within lymphoid aggregates (Fig. 4g, h ). However, PD-1 hi CXCR5 − cells outnumbered PD-1 hi CXCR5 + cells within lymphoid aggregates, and were around fourfold more abundant than PD-1 hi CXCR5
+ cells in regions outside of lymphoid aggregates (Fig. 4h) . Within lymphoid aggregates, both PD-1 hi CXCR5 − cells and PD-1 hi CXCR5 + cells were found adjacent to B cells (Fig. 4g, i) . However, in areas outside of lymphoid aggregates, the majority of PD-1 hi cells adjacent to B cells were CXCR5 . T PH cells may infiltrate chronically inflamed tissues, which would not be expected to readily recruit T FH cells, providing a potential mechanism for the initiation of ectopic lymphoid structures [21] [22] [23] . T PH -cell production of CXCL13 and IL-21 may recruit both T FH and B cells, promoting local autoantibody production that may not be reflected in serum, and perhaps modulating other B-cell functions such as cytokine production 7, 24 . Identification of the T PH cell phenotype considerably expands the spectrum of B-cell-helper T cells that may be assessed as biomarkers for autoantibody-associated diseases. Further, high expression of PD-1 on T PH cells may offer a potential strategy for therapeutic targeting of tissue T-B-cell interactions.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Synovial fluid samples were obtained as excess material from a separate cohort of patients undergoing diagnostic or therapeutic arthrocentesis of an inflammatory knee effusion as directed by the treating rheumatologist. These samples were de-identified; therefore, additional clinical information was not available, except for the three patients from whom paired synovial fluid and blood were obtained.
Blood samples for clinical phenotyping were obtained from patients seen at the Brigham and Women's Hospital Arthritis Center. For blood cell analyses in the cross-sectional cohort, CDAI was measured by the treating clinician on the day of sample acquisition. Anti-CCP titers were measured using the Immunoscan CCPLus ELISA (Eurodiagnostica), with a positive result defined as > 25 units per ml. For patients with RA that were followed longitudinally, a new treatment was initiated at the discretion of the treating physician, and CDAIs were determined at each visit by trained research study staff. Blood samples were acquired before initiation of a new biologic therapy or within 1 week of starting methotrexate. Concurrent prednisone at doses ≤ 10 mg d −1 were permitted. All synovial fluid and blood samples were subjected to density centrifugation using Ficoll-Hypaque to isolate mononuclear cells, which were cryopreserved for batched analyses. Most phenotypic and transcriptomic analyses of blood T cells were performed on samples from both RA patients and non-inflammatory controls, with similar results unless specifically indicated. In vitro PD-1 hi T cell interconversion assays and in vitro B-cell-helper assays using T cells from the blood were performed using PBMC from blood bank leukoreduction collars from anonymous donors.
All blood CD4 + T cell analyses included only CD45RA − memory CD4 + T cells, except where naive (CD45RA + ) cells are specifically indicated. Here the term 'memory' is used to denote an 'antigen-experienced' status indicated by loss of the naive T-cell marker CD45RA. This population includes both resting and activated antigen-experienced T cells. Synovial fluid and tissue analyses also utilize only memory CD4 + T cells unless total CD4 + T cells are indicated. Naive T cells constituted < 10% of the total population of CD4 + T cells in synovial tissue and synovial fluid. Synovial tissue analysis. Synovial samples were acquired from discarded arthroplasty tissue. Synovial tissue was isolated by careful dissection, minced, and digested with 100 μ g ml −1 LiberaseTL and 100 μ g ml −1 DNaseI (both Roche) in RPMI (Life Technologies) for 15 min, inverting every 5 min. Cells were passed through a 70-μ m cell strainer, washed, subjected to red blood cell lysis, and cryopreserved in Cryostor CS10 (BioLife Solutions) for batched analyses. Mass cytometry. Cryopreserved disaggregated synovial cells or PBMCs were thawed into RPMI and 10% FBS (HyClone). Viability was assessed with rhodium for PBMCs and cisplatin (both Fluidigm) for synovial cells. Cells were then washed and stained with primary antibody cocktails at 1:100 dilution (Extended Data Table 1 ). All antibodies were obtained from the Longwood Medical Area CyTOF Antibody Resource Core (Boston, Massachusetts). Cells were then washed, fixed and permeabilized using the Ebioscience Transcription Factor Fix/Perm Buffer for 45 min, washed in PBS/1% BSA/0.3% saponin, then stained for intracellular markers. Cells were re-fixed in formalin (Sigma), washed with Milli-Q water, and analysed on a CyTOF2 (Fluidigm) for PBMC or Helios (Fluidigm) for synovial cells. Mass cytometry data were normalized using EQ Four Element Calibration Beads (Fluidigm) as described 25 . viSNE analyses were performed on cytometry data from 3 of 6 synovial tissue samples, 3 of 9 synovial fluid samples, and 8 of 14 blood samples using the Barnes-Hut SNE implementation on Cytobank (http://www.cytobank.org). All three individual synovial tissue sample analyses are shown. For synovial fluid and blood cell analyses, one representative patient sample is shown. For synovial tissue mass cytometry data, gated CD4 + T cells were analysed using all available protein markers, and each synovial tissue sample was analysed individually to allow for maximal resolution. For paired synovial fluid and blood flow cytometry data, gated memory CD4 + T cells from synovial fluid and blood were analysed together in a single viSNE analysis for direct comparison using an equal number of randomly selected cells from each sample. For blood mass cytometry analyses, equal numbers of gated memory CD4 + T cells from each sample were analysed together using all markers except those used for gating (CD3, CD4, CD45RO). Comparison of marker expression on PD-1 hi CXCR5 − and PD-1 hi CXCR5 + cells was performed with R-3.2 using Mann-Whitney tests and P values were adjusted for multiple testing using the Bonferroni correction. Mass cytometry data were transformed using the inverse hyperbolic sine before expression analysis 25 as in Fig. 3b . Flow cytometry and cell sorting. For PD-1 hi T-cell quantification, cryopreserved cells were thawed into warm RPMI/10% FBS, washed once in cold PBS, and stained in PBS/1% BSA with the following antibodies for 45 min: anti-CD27-FITC (TB01), anti-CXCR3-PE (CEW33D), anti-CD4-PE-Cy7 (RPA-T4), anti-ICOS-PerCP-Cy5.5 (ISA-3), anti-CXCR5-BV421 (J252D4), anti-CD45RA-BV510 (HI100), anti-HLA-DR-BV605 (G46-6), anti-CD49d-BV711 (9F10), anti-PD-1-APC (EH12.2H7), anti-CD3-AlexaFluor700 (HIT3A), anti-CD29-APC-Cy7 (TS2/16), propidium iodide. Antibodies used in additional panels included anti-SLAM-AF488 (A12), anti-SLAMF5-PE (CD84.1.21), anti-SLAMF6-PE (NT-7), anti-CCR2-PE (K036C2), anti-CX3CR1-FITC (2A9-1), anti-CD38-PE (HIT2), anti-CD138-PE/Cy7 (MI15), anti-CTLA-4-PerCP/Cy5.5 (L3D10) from BioLegend, anti-CCR5-FITC (2D7) and anti-FoxP3-AF647 (236A/E7) from BD Biosciences, anti-LAG-3-APC from R&D Systems, anti-TIM-3-PE/Cy7 (F38-2E2) and anti-TIGIT-PE (MBSA43) from eBioscience.
Cells were washed in cold PBS, passed through a 70-μm filter, and data acquired on a BD FACSAria Fusion, BD Fortessa, or BD Canto II analyser using FACSDiva software. Data were analysed using FlowJo 10.0.7. For blood cell quantification in 
CD4
+ T cells sorted as above were pelleted by centrifugation and resuspended in RPMI/10% FBS at a density of 5 × 10 5 cells per ml in 24-well plates. Cells were stimulated with either anti-CD3/anti-CD28 beads at a ratio of 2:1 (cell:bead) for 24 h, or with phorbol 12-myristate 13-acetate (PMA, 50 ng ml −1 ) and ionomycin (1 μ g ml −1 ) for 6 h. Brefeldin A and monensin (both 1:1,000, eBioscience) were added for the last 5 h. Cells were washed twice in cold PBS, incubated for 30 min with Fixable Viability Dye eFluor 455UV (eBioscience), washed in PBS/1% BSA, and then fixed and permeabilized using the eBioscience Transcription Factor Fix/Perm Buffer. Cells were washed in PBS/1% BSA/0.3% saponin and incubated with anti-IL-21-APC (3A3-N2), anti-IL-2-PE/Cy7 (MQ1-17H12), and anti-CXCL13-AlexaFluor700 (53610, R&D Systems) for 30 min, washed once, filtered, and data acquired on a BD Fortessa analyser. Intracellular transcription factor staining. Synovial tissue and synovial fluid cells were thawed, washed twice in PBS, and incubated with Fixable Viability Dye eFluor 455UV (eBioscience) for 30 min. Cells were then washed in PBS/1% BSA and stained with antibodies against surface markers anti-CD3-AF700, anti-CD4-BV650, anti-CCR2-PE, anti-CXCR5-BV421, anti-PD-1-PE/Dazzle 594 (all Biolegend) for 30 min. Cells were washed once and incubated with eBioscience Transcription Factor Fix/Perm Buffer. Cells were washed in PBS/1% BSA/0.3% saponin and incubated in intracellular antibodies anti-MAF-PerCPeFluor710 (sym0F1, eBioscience), anti-Bcl6-APC (BCL-UP, eBioscience), and anti-Blimp-1-AF488 (646702, R&D Systems) at 1:20 dilutions for 4 h. Cells were washed once, filtered, and data acquired on a BD Fortessa analyser. Intracellular detection of FoxP3 and CTLA-4 were performed by the same letter reSeArCH method on magnetic-bead purified blood CD4 + T cells using the indicated surface markers. RT-PCR analyses. RNA was isolated using RNeasy Micro Kits (Qiagen). cDNA was prepared using Quantitect RT-PCR (Qiagen) and PCR performed with Brilliant III SYBRGreen on an a Stratagene Mx3000. Primers used were as follows: RPL13A (forward: 5′ -CATAGGAAGCTGGGAGCAAG-3′ ; reverse: 5′ -GCCCTCC AATCAGTCTTCTG-3′ ), IL2 (forward: 5′ -AGAACTCAAACCTCTGG AGGAAG-3′ ; reverse: 5′ -GCTGTCTCAGCATATTCACAC-3′ ), IFNG (forward: 5′ -GCATCGTTTTGGGTTCTCTTG-3′ ; reverse: 5′ -AGTTCCATTA TCCGCTACATCTG-3′ ), IL10 (forward: 5′ -CGCATGTGAACTCCCTGG-3′ ; reverse: 5′ -TAGATGCCTTTCTCTTGGAGC-3′ ), IL21 (forward: 5′ -AGGAAA CCACCTTCCACAAA-3′ ; reverse: 5′ -GAATCACATGAAGGGCATGTT-3′ ), CXCL13 (forward: 5′ -TCTCTGCTTCTCATGCTGCT-3′ ; reverse: 5′ -TCAAGC TTGTGTAATAGACCTCCA-3′ ), PD1 (forward: 5′ -CCAGGATGGTTCTTA GACTCC-3′ ; reverse: 5′ -TTTAGCACGAAGCTCTCCGAT-3′ ), CXCR5 (forward: 5′ -GGGAGCCTCTCAACATAAGAC-3′ ; reverse: 5′ -CCAATCTGTCC AGTTCCCAGA-3′ ), MAF (forward: 5′ -CCGTCCTCTCCCGAGTTTTT-3′ ; reverse: 5′ -TGCTGGGGCTTCCAAAATGT-3′ ), BCL6 (forward: 5′ -GT TTCCGGCACCTTCAGACT-3′ ; reverse: 5′ -CTGGCTTTTGTGACG GAAAT-3′ ), BATF (forward: 5′ -TGGCAAACAGGACTCATCTG-3′ ; reverse: 5′ -CTGTTTCTCCAGGTCTTCGC-3′ ), SAP (forward: 5′ -GCTATTTGCTGA GGGACAGC-3′ ; reverse: 5′ -TGTCTGGGACACTCGGTATG-3′ ), BLIMP1 (forward: 5′ -AACTTCTTGTGTGGTATTGTCGG-3′ ; reverse: 5′ -TCTCAGTGCTCGGTTGCTTT-3′ ). Expression levels relative to control gene RPL13A were calculated. RNA sequencing. RNA was isolated from 800-1,000 cells from sorted T-cell subpopulations as described. 5 μl of total RNA were placed in wells of a 96-well plate and RNA sequencing libraries were prepared at Broad Technology Labs at the Broad Institute of Harvard and MIT using the Illumina SmartSeq2 platform. Samples were sequenced on a NextSeq500 using 75 bp paired-end reads to an average depth of 9 M pairs of reads per sample. All cDNA transcripts from Ensembl release 82 were quantified with Kallisto version 0.42.4 (ref. 26) . We used limma to model each gene as a linear combination of donor-specific effects. The residuals from these models were tested by ANOVA across 8 gates, and 581 genes with a significant F statistic with < 5% FDR were selected for PCA. + expression values. In comparisons of specific cell populations, genes with log fold change > 1.2 and FDR < 1% were considered differentially expressed. PD-1 hi cell in vitro stimulation assays. CD4 + T cells were purified from PBMCs from blood bank leukoreduction collars by magnetic bead negative selection and stained with anti-CD4-BV650, anti-CD45RA-BV510, anti-PD-1-APC, anti-CXCR5-BV605, and anti-CCR2-PE/Cy7. Naive CD4 + T cells and memory CD4 + T-cell subpopulations were sorted into RPMI/10% FBS. 50,000 cells were resuspended in RPMI/10% FBS at 0.25 × 10 6 cells ml −1 and cultured with anti-CD3/ CD28 beads (Dynabeads) at a cell:bead ratio of 5:1 for 2 or 7 days. Cells were then either re-stained with anti-PD-1-PE and anti-CXCR5-BV421 antibodies and sorted into lysis buffer for RT-PCR analyses, or stained with anti-CCR2-PE and anti-CXCR5-BV421 and analysed by intracellular flow cytometry for transcription factors as above. T-B-cell co-cultures. Total B cells were isolated first from PBMCs from blood bank leukoreduction collars by magnetic bead positive selection using CD19 (Miltenyi), then CD4
+ T cells were isolated by negative selection. B cells were stained with anti-CD14-APC, anti-CD3-PeCy7, and anti-CD27-BV510 antibodies (all from Biolegend), and memory B cells sorted as CD27 + CD14 − CD3 − cells on a BD FACSAria Fusion to remove contaminating T cells and monocytes. Sorted T-cell populations were co-cultured with autologous memory B cells at a ratio of 1:10 in 100 μ l of RPMI/10% FBS and stimulated with LPS (5 μ g ml −1
) and SEB (1 μ g ml IL-21R-Ig (R&D Systems) were used. Immunofluorescence microscopy. 6-μm sections of synovium frozen in OCT were fixed in acetone, rehydrated in PBS, and blocked with 10% normal goat serum before application of primary antibodies as follows: PD-1 (EH12.2H7, BioLegend), CD3 (SP7, Abcam), CD20 (L26, Dako), CXCR5 (MAB190, R&D Systems), all at a dilution of 1:100 except for CD20, which was used at 1:300. All secondary antibodies were raised in goat. CXCR5 was detected using anti mouse IgG2b biotin (Southern biotech) followed by streptavidin conjugated AlexaFluor 546 (Life Technologies), CD20 with anti-mouse IgG2a FITC (both Southern Biotech), PD-1 with anti-mouse IgG1 conjugated to AlexaFluor 647 and CD3 with anti-rabbit AlexaFluor 546 (both Life Technologies). FITC staining was amplified with anti-FITC AlexaFluor 488 (Life Technologies). Slides were mounted using ProLong Diamond (Life Technologies), left to cure overnight and imaged using a Zeiss LSM 780 confocal microscope. Images were processed using Zen Black (Zeiss) and then ImageJ. Cell counts were performed on images obtained from confocal imaging using the Cell Counter plugin for ImageJ (imagej.net/Cell_Counter). Synovial regions were categorized as 'lymphoid aggregates' when the B cells and T cells formed distinct clusters, and 'diffusely infiltrated' when B cells were loosely distributed within the synovium. Statistical analyses. Statistical comparisons were performed as indicated in figure legends using two-sided tests. P values < 0.05 were considered significant after adjusting for multiple testing using the Bonferroni correction for ANOVA (Fig. 2d ) and blood mass cytometry analysis (Fig. 3b) , or Dunn's test for non-parametric multi-group comparisons. Data availability. The RNA-seq dataset is available at the ImmPort repository, accession number SDY939 (https://www.immport.org/immport-open/public/ study/study/displayStudyDetail/SDY939). The data that support the findings of this study are available from the corresponding author upon reasonable request. + T cells from blood of patients with seropositive RA (n = 42), seronegative RA (n = 16), spondyloarthropathy (SpA, n = 11), and non-inflammatory controls (n = 35). f, Correlation between age or disease duration and blood PD-1 hi CXCR5 − cell frequency in seropositive RA patients (n = 38). g, PD-1 hi CXCR5 − cell frequencies in seropositive RA patients segregated based on sex or medication usage (n = 38). h, Correlation between serum anti-CCP antibody titer and blood PD-1 hi CXCR5 − cell frequency in all RA patients (n = 53, black line, P = 0.0049) or in only anti-CCP antibody + patients (n = 29, green line, P = 0.48). i, Correlation between fold change in CDAI and fold change in PD-1 hi CXCR5 − cell frequency in patients 3 months after addition of a new RA medication (n = 23; methotrexate, 11; anti-TNF, 4; abatacept, 4; tocilizumab, 2; tofacitinib, 2). j, Frequency of PD-1 hi T-cell subpopulations in blood before and after RA treatment escalation in 18 patients with reduced disease activity after therapy. Median ± interquartile range (c-e); mean ± s. d. (a, g) shown. * P < 0.05, * * P < 0.01, * * * P < 0.001, * * * * P < 0.0001 by Mann-Whitney (c, g), Kruskal-Wallis (d, e), Wilcoxon test (j). In f, h, i, P values calculated by Spearman correlation. 
